MAR 1 6 2004 20 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: HOFFMAN=9

In re Application of:

Arnold HOFFMAN

Appln. No.: 10/621,326

Filed: July 18, 2003

For: REDOX THERAPY FOR TUMORS

Confirmation No.: 2518

Examiner:

Washington, D.C.

March 16, 2004

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents U.S. Patent and Trademark Office 2011 South Clark Place Crystal Plaza Two, Lobby, Room 1B03 Arlington, Virginia 22202

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

- 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed before the mailing date of a first Office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114.
- 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., Form PTO/SB/08A) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an

In re Appln. No. 10/621,326

Ä

attachment hereto. A copy of each document listed is attached, except as explained below.

- [X] C. Document BM is U.S. patent and/or published application. As this is a U.S. application filed after June 30, 2003, or an entry into national stage under 35 USC §371 after June 30, 2003, the requirement to file copies of such U.S. patents or published applications has been waived. (Office of Patent Legal Administration Pre O.G. Notice of July 11, 2003).
- 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- 4. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By:

Sheridan Neimark Reg. No. 20,520

SN:msp:jaa

624 Ninth Street, N.W., Suite 300

Washington, D.C. 20001-5303

Telephone: (202)628-5197 Facsimile: (202)737-3528 G:\BN\B\BENA\HOFFMAN9\PTO\IDS2004.doc

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE quired to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are

Sheet

MAR 1 6 2004

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 10/621,326 **Application Number** Filing Date July 18, 2003 Arnold HOFFMAN First Named Inventor 1614 Group Art Unit Confirmation Number 2518 HOFFMAN=9 Attorney Docket Number

(use as many sheets as necessary)

U.S. PATENT DOCUMENTS Document Number **Publication Date** Name of Patentee or Pages, Columns, Lines, Where Cite Number-Kind Code^{2 (if know} Applicant of Cited Document Relevant Passages or Relevant MM-DD-YYYY Examiner Figures Appear nitials* No. US-6,589,987 B2 07-08-2003 KENNEDY ВМ US-US-บรuslusus. us-US-USus. us. USus-US-US-US-

FOREIGN PATENT DOCUMENTS								
Examiner Initials*		Foreign Patent Number		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°		
	Cite No.1	Country Code ³ Number ⁴ Kind Code ⁵ (<i>it known</i>)						
			· · · · · · · · · · · · · · · · · · ·					

Examiner	Date
Signature	Considered
Signature	Considered

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 195, no persons are equired to respond to a collection of information unless it contains a valid OMB control number.

MAR 1 6 2004

Complete if Known PRADERAL Substitute for form 1449A/PTO 10/621,326 **Application Number** INFORMATION DISCLOSURE Filing Date July 18, 2003 STATEMENT BY APPLICANT Arnold HOFFMAN First Named Inventor 1614 Group Art Unit 2518 (use as many sheets as necessary) **Confirmation Number** HOFFMAN=9 Sheet Attorney Docket Number

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS									
Examiner Initials*	Cite No.1								
	BN	BAILEY, et al., "Phase I clinical trail of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione", <u>Journal of Clinical Oncology</u> . January 1994, Vol. 12, No. 1, 194-205.							
	во	NODA, et al., "Induction of Mild Intracellular Redox Imbalance Inhibits Proliferation of CaCo-2 Cells", <u>FASEB</u> <u>Journal</u> . October 2001, Vol. 15, 2131-2139.							
			•						
:									
Evamir	or.	Date	1						
Examiner Signature		Considered	1						

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.